HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
The Centers for Disease Control and Prevention released a Health Alert Network Health Update May 18 informing clinicians about testing available for patients…
Headline
An outbreak of measles in Utah has grown to 663 cases, the state’s Department of Health and Human Resources reported May 12. There have been 466 cases…
Headline
A Centers for Disease Control and Prevention report released May 14 found that U.S.-reported dengue cases in 2024 increased 359% above the annual average from…
Headline
The Centers for Disease Control and Prevention announced May 14 that 41 people across the U.S. are being monitored for symptoms of hantavirus following an…
Headline
The measles outbreak in Utah that began in June 2025 has grown to 638 cases as of May 5, according to the state’s Department of Health and Human Services. Of…
Headline
A measles outbreak that reached 997 cases in South Carolina has been declared over, as the 42-day threshold with no new reported cases was reached April 26.…